贵州信邦制药股份有限公司 2020 年第一季度报告全文 贵州信邦制药股份有限公司 2020 年第一季度报告 2020 年 04 月 1 贵州信邦制药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 除下列董事外，其他董事亲自出席了审议本次季报的董事会会议 未亲自出席董事姓名 未亲自出席董事职务 未亲自出席会议原因 被委托人姓名 朱吉满 董事 个人原因 胡晋 公司负责人安怀略、主管会计工作负责人及会计机构负责人(会计主管人员) 肖娅筠声明：保证季度报告中财务报表的真实、准确、完整。 2 贵州信邦制药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|--------- ...

Financial Performance - Operating revenue for the period was ¥1,740,531,376.49, reflecting a slight decline of 0.62% year-on-year[9] - Net profit attributable to shareholders was ¥78,834,004.57, an increase of 15.46% compared to the same period last year[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥79,137,650.95, up by 18.47% year-on-year[9] - Basic earnings per share were ¥0.05, representing a 25.00% increase year-on-year[9] - Net profit for the period was CNY 83,044,593.40, an increase of 17.43% from CNY 70,716,108.82 in the previous period[64] - The company reported a net profit of ¥199,472,127.57 for the current period, down from ¥266,415,509.78, a decline of about 25.0%[82] - The company reported a net loss of CNY 162,847,037.07 in retained earnings, compared to a loss of CNY 363,001,551.82 in the previous period[50] Cash Flow - Net cash flow from operating activities reached ¥274,793,567.01, a significant increase of 6,191.58% compared to the same period last year[9] - Cash flow from operating activities generated a net amount of ¥573,454,506.88, a significant recovery from a negative cash flow of -¥388,536,237.63 in the previous period[95] - Cash inflow from operating activities totaled ¥5,210,311,102.56, compared to ¥5,149,268,214.15 in the previous period, indicating a growth of 1.2%[95] - Operating cash inflow for the period was CNY 434,925,970.73, a decrease of 12.1% compared to CNY 494,758,921.83 in the previous period[106] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥10,259,339,563.29, a decrease of 5.48% compared to the end of the previous year[9] - The company’s total current assets decreased to ¥5,929,447,039.52 from ¥6,673,395,049.95, reflecting a reduction in cash and inventory[41] - Total liabilities amounted to CNY 5,195,072,028.57, a decrease of 8.63% compared to CNY 5,685,795,483.98[49] - Current liabilities decreased to CNY 4,847,058,106.98, down 9.15% from CNY 5,337,289,924.54[47] - The company's equity attributable to shareholders decreased to CNY 4,881,211,593.79, down 1.73% from CNY 4,967,457,613.02[50] Shareholder Information - The company reported a total of 61,911 common shareholders at the end of the reporting period[15] - The top shareholder, Tibet Yuxi Venture Capital Co., Ltd., held 21.52% of the shares, totaling 358,764,349 shares[15] - The company did not engage in any repurchase transactions during the reporting period[20] - The company repurchased a total of 53,428,388 shares, accounting for 3.20% of the total share capital, with a total transaction amount of ¥287,744,229.22[28] Expenses - Financial expenses increased by 49.10% to ¥98,302,730.42 from ¥65,932,519.73 due to higher interest expenses and reduced exchange gains[25] - Research and development expenses increased to CNY 7,772,069.61, compared to CNY 5,744,290.32, marking a rise of approximately 35.36%[61] - The company’s financial expenses rose to CNY 40,545,578.16 from CNY 20,526,634.29, indicating an increase of about 97.80%[61] Other Income and Investments - Other income increased by 168.71% to ¥11,440,973.70 from ¥4,257,757.67 due to increased government subsidies received[25] - Investment income showed a significant change, with a loss of ¥6,129,584.36 in the previous year turning into a gain of ¥2,477,394.87 this year[25] - The company’s other equity instrument investments increased to ¥146,879,478.21 following a change in accounting policy[25] Comprehensive Income - The company reported a decrease in other comprehensive income after tax to CNY 1,176,617.39 from CNY 20,675,717.78, a significant drop of about 94.31%[68] - The company’s other comprehensive income after tax was ¥1,392,644.32, down from ¥19,663,956.80, a decrease of approximately 92.9%[82]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2019, representing a year-on-year increase of 15%[19]. - Net profit attributable to shareholders reached 200 million RMB, up 10% compared to the same period last year[19]. - The company's operating revenue for the reporting period was RMB 3,277,630,244.01, representing a slight increase of 0.12% compared to the same period last year[26]. - The net profit attributable to shareholders decreased by 37.99% to RMB 121,320,510.18 from RMB 195,638,794.21 in the previous year[26]. - The net cash flow from operating activities improved significantly, reaching RMB 298,660,939.87, a 177.77% increase compared to the previous year's negative cash flow[26]. - The basic and diluted earnings per share both decreased by 41.67% to RMB 0.07 from RMB 0.12 in the same period last year[26]. - The net profit for the period was CNY 116.43 million, a year-on-year decrease of 40.51%[51]. - The company reported a significant increase in other income, which rose by 140.37% to RMB 6,567,112.92, attributed to increased government subsidies[54]. - The company reported a total revenue of 490,154,300, with a net profit of 93,298,156.11, reflecting a significant performance in the reporting period[90]. Market Expansion and Product Development - The company plans to expand its market presence by increasing the number of retail pharmacies by 20% by the end of 2019[19]. - The company has launched two new products in the first half of 2019, contributing to a 5% increase in market share[19]. - Future guidance estimates a revenue growth of 12% for the second half of 2019, driven by new product launches and market expansion[19]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[19]. - The company is focusing on enhancing its clinical teaching capabilities and has initiated the construction of a clinical teaching center in collaboration with Guizhou Medical University[51]. - The company is increasing its investment in the research and development of new in vitro diagnostic reagents, with production quality systems meeting EU standards[51]. Operational Risks and Challenges - The company faces various operational risks, including regulatory changes and market competition, which it has outlined in its risk management strategy[6]. - The company faces industry risks due to declining drug prices and potential impacts from policies like medical insurance cost control and drug bidding[93]. - Market competition is intensifying as the healthcare sector evolves, presenting both opportunities and challenges for the company[93]. - Rising costs from raw materials and labor are expected to impact future profitability, highlighting the need for effective cost management[93]. - The company is investing in new drug research and development, which carries risks due to stringent regulatory requirements and potential delays[93]. Financial Management and Investments - The company has a total of CNY 30,311.97 million planned for investment in various hospital projects, with actual investment of CNY 466.31 million reported[80]. - The company has not engaged in any securities or derivative investments during the reporting period[69][70]. - The company has committed to compensating for any losses incurred due to the lack of property certificates for rental properties, with cash compensation promised within 10 days of loss occurrence[103]. - The company has a total of 18,050 million in procurement from the provincial medical procurement platform[152]. - The company has approved a total external guarantee amount of 20,000 million, with an actual guarantee amount of 20,000 million for a related party[162]. Social Responsibility and Environmental Compliance - Guizhou Xibang Pharmaceutical is committed to social responsibility through targeted poverty alleviation, focusing on industrial and medical support to enhance self-development capabilities in impoverished areas[192]. - The company invested approximately CNY 4.21 million in poverty alleviation efforts in the first half of 2019, with CNY 3.25 million allocated to health poverty alleviation benefiting over 25,000 people[194]. - The company has established a wastewater treatment station that meets national standards before discharging into the municipal sewage system[188]. - The company has signed agreements with qualified operators for the disposal of medical waste, ensuring compliance with relevant regulations[188]. - The company has implemented a dynamic management approach to its poverty alleviation initiatives, ensuring continuous improvement and adaptation[193]. Corporate Governance and Compliance - The company will ensure that any related transactions do not harm the interests of minority shareholders[121]. - The company has committed to a lock-up period of 36 months for shares acquired during the transaction, adhering to regulations set by the China Securities Regulatory Commission[131]. - The company has guaranteed to protect the interests of minority shareholders in related party transactions[134]. - The company will strictly adhere to the regulations set forth by the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding shareholder rights and obligations[121]. - The company has made a long-term commitment to fulfill its obligations regarding the acquisition and operational independence[115].

Financial Performance - The company's revenue for Q1 2019 was ¥1,561,306,722.03, representing a 3.27% increase compared to ¥1,511,849,327.74 in the same period last year[9]. - Net profit attributable to shareholders decreased by 16.09% to ¥61,806,270.12 from ¥73,656,330.34 year-on-year[9]. - The net cash flow from operating activities improved significantly, reaching ¥108,319,994.99, a 214.52% increase from -¥94,584,056.65 in the previous year[9]. - Total assets at the end of the reporting period were ¥10,623,821,002.75, down 2.12% from ¥10,854,314,146.17 at the end of the previous year[9]. - Net assets attributable to shareholders decreased by 4.03% to ¥4,767,455,492.33 from ¥4,967,457,613.02 year-on-year[9]. - Basic and diluted earnings per share remained unchanged at ¥0.04[9]. - The weighted average return on net assets increased slightly to 1.24% from 1.14% year-on-year[9]. - Total operating revenue for the current period reached ¥1,561,306,722.03, an increase of 3.3% compared to ¥1,511,849,327.74 in the previous period[92]. - Total operating costs amounted to ¥1,498,513,309.52, up from ¥1,422,504,445.43, reflecting a year-over-year increase of 5.3%[92]. - Net profit for the current period was ¥49,414,027.31, a decrease of 21.6% from ¥63,103,688.02 in the previous period[95]. - Research and development expenses increased to ¥12,406,438.54, compared to ¥8,173,094.05, marking a rise of 51.5%[92]. Shareholder and Ownership Changes - The top shareholder, Tibet Yuxi Investment Co., Ltd., holds 21.52% of the shares, totaling 358,764,349 shares[13]. - Guizhou Xibang Pharmaceutical Co., Ltd. reported a significant change in its major shareholder, with Tibet Yuxi Venture Capital Co., Ltd. becoming the largest shareholder after acquiring 358,764,349 shares[32]. - The acquisition of shares was funded entirely through self-raised capital, with no involvement of funds from Guizhou Xibang Pharmaceutical or its subsidiaries[32]. - The company has committed to avoiding any business competition with its controlling shareholder, ensuring that no funds or assets are misappropriated from Guizhou Xibang Pharmaceutical[32]. - The company has committed to disclosing any related transactions in accordance with legal and regulatory requirements[32]. Compliance and Regulatory Commitments - The company is focused on maintaining compliance with relevant laws and regulations during the transition of control[32]. - The company has committed to avoid any business activities that may compete with Xinbang Pharmaceutical after acquiring its controlling stake[35]. - The company will ensure that all senior management personnel are exclusively employed by the listed company and do not hold operational roles in the information disclosure obligor[36]. - The company will conduct transactions with related parties based on fair and reasonable principles[54]. - The company has established a framework to ensure compliance with relevant laws and regulations regarding shareholder rights and obligations[60]. Asset Management and Financial Health - Other current assets decreased by 57.90% to 7,550,049.65 due to a decline in tax credits[20]. - Interest payable increased by 306.26% to 5,974,000.00 as a result of accrued bond interest[20]. - Cash flow from investing activities improved by 61.33% to -42,110,290.02, with no acquisitions of subsidiaries this period[20]. - Total current assets decreased from ¥6,673,395,049.95 to ¥6,454,377,838.71, a decline of approximately 3.29%[75]. - Total non-current assets slightly decreased from ¥4,180,919,096.22 to ¥4,169,443,164.04, a decrease of about 0.18%[75]. - Total liabilities decreased from ¥5,685,795,483.98 to ¥5,668,912,655.11, a decline of approximately 0.30%[78]. - Total equity decreased from ¥5,168,518,662.19 to ¥4,954,908,347.64, a decrease of about 4.14%[81]. Operational Commitments and Future Plans - The company has no plans for major adjustments to its main business or asset restructuring in the next 12 months[41]. - There are no plans to adjust the existing dividend policy within the next 12 months, except as required by regulatory authorities[44]. - The company will continue to acquire the remaining 0.19% equity of Keke Medicine at a price of 10 yuan per share[44]. - The company has no significant plans that would impact its business and organizational structure beyond what has been disclosed[44]. - The company is committed to ensuring independent operations and minimizing related transactions with its subsidiaries[41]. Risk Management and Liabilities - The company reported a commitment from transaction parties to compensate for losses incurred due to properties without ownership certificates, with compensation based on shareholding ratios[47]. - There are four rental properties under the company that lack ownership certificates, but the risk of demolition is considered low due to their use as medical facilities[47]. - The company has a commitment from transaction parties to cover any costs exceeding 4 million RMB related to land use rights issues at Anshun Hospital[47]. - The company emphasizes that no related parties will engage in competitive activities that harm the interests of the company and its minority shareholders[50]. - The company has committed to taking effective measures to prevent any conflicts of interest with its subsidiaries[50].

Financial Performance - The company reported a cash dividend of 0.00 CNY per 10 shares, with no stock bonus or capital increase from reserves[4]. - The company's operating revenue for 2018 was ¥6,580,278,918.05, an increase of 9.63% compared to ¥6,002,471,030.96 in 2017[21]. - The net profit attributable to shareholders was -¥1,296,605,450.24, a decrease of 505.97% from ¥319,383,501.24 in 2017[21]. - The net cash flow from operating activities was -¥218,563,061.59, a decline of 208.34% compared to ¥201,742,949.00 in 2017[21]. - The total assets at the end of 2018 were ¥10,854,314,146.17, down 9.21% from ¥11,954,952,353.81 at the end of 2017[21]. - The net assets attributable to shareholders decreased by 24.91% to ¥4,967,457,613.02 from ¥6,615,306,677.94 in 2017[21]. - The basic earnings per share for 2018 was -¥0.80, a decrease of 521.05% from ¥0.19 in 2017[21]. - The company reported a net profit of -1,296,605,450.24 CNY for 2018, marking its first loss since listing[119]. - The company’s available distributable profit as of December 31, 2018, was -825,381,603.11 CNY[119]. - The company reported a total revenue of 986,783,025.99, with a net profit of 211,936,281.62 for the reporting period[1]. Business Segments and Operations - The company operates in three main business segments: medical services, pharmaceutical distribution, and pharmaceutical manufacturing, with no significant changes in business model or performance drivers during the reporting period[29]. - The medical services segment's revenue increased by 16.29% to CNY 1,555,240,196.92, contributing 23.63% to total revenue[46]. - The pharmaceutical distribution segment generated CNY 4,224,514,382.49 in revenue, accounting for 64.20% of total revenue, with an 11.99% increase year-on-year[46]. - The total sales volume in the pharmaceutical distribution sector increased by 29.98% to 517,086,055 units in 2018 from 397,807,489 units in 2017[50]. - The total production volume in the pharmaceutical manufacturing sector decreased by 28.50% to 74,023,240.69 units in 2018 from 103,521,925 units in 2017[53]. Investments and Acquisitions - The company has initiated the construction of new hospital facilities, including the third phase of the cancer hospital and the main building of the Bodai Hospital, indicating ongoing investment in infrastructure[30]. - The company made significant equity investments, including a $16.20 million increase in Guizhou Zhongkangze Medical Equipment Co., acquiring 100% ownership[74]. - The company completed multiple acquisitions in the pharmaceutical sector, including a $10.20 million acquisition of Guizhou Anshen Pharmaceutical Co., holding a 51% stake[76]. - The company reported an investment loss of approximately -$5.92 million, which accounted for 0.49% of total profit[68]. Research and Development - The company’s new product development includes innovative peptide drugs, supported by national project funding[44]. - The company has increased its inventory of traditional Chinese medicine raw materials, reflecting a strategic focus on enhancing product quality and supply chain stability[33]. - The company's R&D expenses rose by 21.60% to ¥36,692,276.40 in 2018, representing 0.56% of operating revenue[63]. - The number of R&D personnel increased by 28.85% to 134 in 2018, representing 1.92% of the total workforce[63]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report, highlighting potential operational risks and mitigation strategies[4]. - The company faces industry risks due to declining drug prices and potential impacts from healthcare reforms[9]. - The company anticipates increased competition in the healthcare sector as market participation rises[10]. - Rising costs from raw materials and labor may affect the company's future profitability[11]. - The company has faced various risks, including human resources, management, environmental, and financial risks, which it aims to manage effectively[114]. Corporate Governance and Compliance - The board of directors confirmed that all members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[3]. - The company has committed to ensuring the completion of property ownership certificates for assets involved in a major asset restructuring, with compensation agreements in place for any losses incurred[128]. - The company has pledged to avoid any related party transactions post-restructuring, ensuring fair and reasonable pricing based on market standards[155]. - The company guarantees compliance with relevant laws and regulations, protecting the rights of shareholders and avoiding improper benefits from controlling shareholder status[159]. Future Plans and Strategies - The company plans to issue medium-term notes not exceeding CNY 1 billion to optimize its debt structure[41]. - The company plans to focus on improving management and profitability in 2019, aiming to enhance asset quality[114]. - The company aims to integrate resources and promote steady development across its various business segments[114]. - The company is actively working on the integration of business operations between Yuheng Pharmaceutical and Xibang Pharmaceutical[146].

贵州信邦制药股份有限公司 2018 年第三季度报告正文 证券代码：002390 证券简称：信邦制药 公告编号：2018-113 贵州信邦制药股份有限公司 2018 年第三季度报告正文 1 贵州信邦制药股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人安怀略、主管会计工作负责人肖娅筠及会计机构负责人(会计主 管人员)肖娅筠声明：保证季度报告中财务报表的真实、准确、完整。 2 贵州信邦制药股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 12,410,083,299.39 | 11,954,952,353.81 | | 3.81% | | ...

贵州信邦制药股份有限公司 2018 年半年度报告全文 贵州信邦制药股份有限公司 2018 年半年度报告 2018 年 08 月 1 贵州信邦制药股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 随着医疗卫生行业的进一步发展，国家医疗改革的不断深入，药品价格呈 下降趋势。公司在未来市场经营过程中，受医保控费、"两票制"、仿制药一致 性评价、药品招投标等政策的影响，如果面临行业平均利润率下降的局面，可 能会对公司未来盈利能力产生不利影响。 （二）市场竞争风险 随着国家推动医疗体制改革向纵深发展，促进健康服务业发展，鼓励社会 资本办医等政策的出台，市场参与度提高，竞争日趋激烈，市场的开拓必将带 来新的发展机会，同时也会使公司面临严峻的市场竞争风险和较大的竞争压力。 （三）成本上涨风险 原材料价格的变化、人力资源成本的上升、固定资产投入加大导致折旧费 用的增加等，导致公司成本呈上涨的趋势，因此公司收入与成本的变动趋势可 能出现不完全相关的情况，对公司未来的盈利能力产生影响。 2 贵州信邦制药股份有限公司 2018 年半年度报告全文 （四）研发风险 公司董事会、监事会及董事、监事、高级管理人员保证 ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.30 CNY per 10 shares (including tax) to all shareholders based on the total share capital on the dividend record date[12]. - The total cash dividend for 2017 is 50,016,858.33 CNY, which represents 20.11% of the distributable profit of 248,730,308.24 CNY[109]. - The net profit attributable to ordinary shareholders for 2017 is 319,383,501.24 CNY, with a dividend payout ratio of 15.66%[108]. - In 2016, the cash dividend was 51,146,873.64 CNY, which accounted for 20.79% of the net profit attributable to ordinary shareholders of 246,012,798.35 CNY[108]. - The company did not propose any stock dividends or capital reserve transfers for the 2017 fiscal year[109]. - The company is in a growth phase and has significant capital expenditure plans, which influences its dividend distribution strategy[109]. Financial Performance - The company's operating revenue for 2017 was CNY 6,002,471,030.96, representing a 16.39% increase compared to CNY 5,157,031,775.28 in 2016[24]. - The net profit attributable to shareholders for 2017 was CNY 319,383,501.24, a 29.82% increase from CNY 246,012,798.35 in 2016[24]. - The net profit after deducting non-recurring gains and losses was CNY 298,103,856.26, which is a 60.45% increase compared to CNY 185,791,839.58 in 2016[24]. - The net cash flow from operating activities improved significantly to CNY 201,742,949.00, a 201.59% increase from a negative CNY 198,585,062.17 in 2016[24]. - The total assets at the end of 2017 were CNY 11,954,952,353.81, reflecting a 10.72% increase from CNY 10,797,081,200.48 at the end of 2016[24]. - The basic earnings per share for 2017 was CNY 0.19, up 26.67% from CNY 0.15 in 2016[24]. - The company’s weighted average return on equity for 2017 was 4.93%, an increase from 4.25% in 2016[24]. Market and Industry Risks - The company faces industry risks due to declining drug prices influenced by national medical reforms, which may adversely affect future profitability[5]. - The company is exposed to market competition risks as healthcare reforms increase market participation and competition intensity[6]. - Rising costs from raw material price fluctuations and increased labor costs may impact the company's future profitability[7]. - The company acknowledges R&D risks due to stricter regulations and the inherent challenges in new drug development[8]. - Environmental protection standards are becoming stricter, necessitating increased investment in environmental compliance, potentially affecting profitability[10]. - The pharmaceutical industry is expected to experience a slowdown in growth due to the implementation of various healthcare reforms, leading to increased industry consolidation[96]. Strategic Initiatives - The company aims to enhance its core competitiveness by maximizing business synergy across its full industry chain, which may require adjustments to management systems[10]. - The company is focused on achieving its operational goals and plans for 2018 despite the outlined risks[12]. - The company is actively expanding its market presence and improving terminal coverage through acquisitions and product diversification[47]. - The company is leveraging its strong R&D capabilities in the peptide field to enhance product value and profitability[43]. - The company is advancing "Internet + Healthcare" initiatives to improve service efficiency and develop personalized family doctor services[100]. - The company plans to enhance its research and innovation capabilities in medical services, particularly through the establishment of a GCP trial base at Baiyun Hospital, expected to be operational by June[97]. Investments and Acquisitions - The company made a significant equity investment of ¥3,060,000 in Guizhou Xinbang Fudun Technology Co., holding a 51% stake, but reported a loss of ¥1,406,159.50 for the period[79]. - A new investment of ¥20,000,000 was made in Zhejiang Yuan Pharmaceutical Technology Co., acquiring a 100% stake, with a reported gain of ¥441,220.85[79]. - The company is involved in ongoing major non-equity investments, including a self-built medical service project at Guizhou Medical University with a total investment of ¥75,126,142.98[80]. - The cumulative investment in the second phase of the Guizhou Medical University project reached ¥302,213,203.75, fully funded by the company's own capital[80]. - The company has identified potential acquisition targets in the medical device sector, with an estimated budget of 10,000 million for acquisitions[156]. Social Responsibility and Community Engagement - The company emphasizes its commitment to social responsibility, focusing on economic, social, and environmental values[166]. - In 2017, the company invested a total of CNY 14.4143 million in poverty alleviation efforts, successfully completing various poverty alleviation plans[170]. - The company organized 60 large-scale free medical consultations and health lectures, benefiting approximately 86,000 participants in 2017[171]. - A total of CNY 1.622 million was waived in medical fees for 5,251 impoverished cancer patients, with CNY 651,800 spent on palliative care services[172]. - The company donated CNY 5 million to establish a medical assistance fund for impoverished patients, addressing healthcare affordability issues[172]. Compliance and Governance - The company has ensured the accuracy and completeness of the information provided during the acquisition process, taking on legal responsibilities for any misrepresentation[111]. - The company has not faced any administrative or criminal penalties related to the securities market since its establishment on July 6, 2016[112]. - The company commits to promoting standardized related party transactions and avoiding competition after becoming the controlling shareholder of Xibang Pharmaceutical[115]. - The company will ensure compliance with relevant laws and regulations to prevent any conflicts of interest or financial misappropriation[115]. - The company has committed to protecting the interests of minority shareholders and adhering to relevant laws and regulations[128]. Environmental Management - The company has established a comprehensive environmental management system to enhance its green competitiveness and reduce emissions[167]. - The company has implemented a wastewater treatment facility that meets environmental standards before discharging into the municipal sewage system[180]. - The company has established emergency response plans for environmental incidents, ensuring preparedness for potential environmental risks[181]. - The company’s environmental monitoring includes automatic systems for real-time tracking of pollutant discharge levels[181]. Future Outlook - The company aims for a revenue growth of no less than 20% year-on-year for 2018[97]. - Future outlook indicates a projected revenue growth of 10% for 2018, with a focus on enhancing product lines and market penetration strategies[124]. - The company is investing in new product development, allocating 100 million yuan towards R&D initiatives in 2018[123].

贵州信邦制药股份有限公司 2018 年第一季度报告正文 证券代码：002390 证券简称：信邦制药 公告编号：2018-051 贵州信邦制药股份有限公司 2018 年第一季度报告正文 1 贵州信邦制药股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人安怀略、主管会计工作负责人肖娅筠及会计机构负责人(会计主 管人员)肖娅筠声明：保证季度报告中财务报表的真实、准确、完整。 2 贵州信邦制药股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,511,849,327.74 | 1,353,978,873.60 | 11.66% | | 归属于上市公司股东的净利 ...

贵州信邦制药股份有限公司 2017 年第三季度报告正文 证券代码：002390 证券简称：信邦制药 公告编号：2017-104 贵州信邦制药股份有限公司 2017 年第三季度报告正文 1 贵州信邦制药股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人安怀略、主管会计工作负责人及会计机构负责人(会计主管人员) 肖娅筠声明：保证季度报告中财务报表的真实、准确、完整。 2 贵州信邦制药股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 11,655,357,548.14 | 10,797,081,200.48 | | 7.95% | | 归属于 ...